We have now examined whether early-stage tau pathology can be attenuated by ultrasound to (i) investigate the efficacy of unilateral FUS, as an adjuvant treatment, for the reduction of phosphorylated human tau in the hippocampus of the rTg4510 mouse model of AD and (ii) identify the response of the FUS-initiated immune reaction to the pathology. Here, MAPT is linked to Alzheimer disease.